



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

24th March 2025
IOLCP/CGC/2025

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051
Security Symbol: **IOLCP**

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001
Security Code: **524164**

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sirs,

In accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we are pleased to inform you of the following updates:

1. Commencement of New Unit 11 for Paracetamol production:

The Company commenced state-of-the-art Unit-11 on 24th March 2025 for manufacturing Paracetamol at its existing location at Barnala with an installed capacity of 10,800 MTPA. Unit-11 is supported by backward integration, with in-house production of key intermediates, Para Amino Phenol (PAP) and Acetic Anhydride, both essential for Paracetamol manufacturing.

The details as required under SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13th July 2023 are given below:

Product Name	Paracetamol
existing capacity;	3,600 MTPA
existing capacity utilization;	3,600 MTPA
proposed capacity addition;	10,800 MTPA
period within which the proposed capacity is to be added;	stands completed on 24/03/2025
investment required;	Total Capex Rs 155.51 crore
mode of financing;	internal accruals
rationale.	The new Unit-11, being state-of-the-art, incorporates the latest advancements in manufacturing technology.

2. Expansion of Clopidogrel Manufacturing Facility (Unit-5):

The Company has enhanced the installed capacity of Unit 5 for manufacturing Clopidogrel Bisulphate from 180 MTPA to 240 MTPA on 24th March 2025 with an capital expenditure of Rs. 7.87 crore funded through internal accruals.



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

The details as required under SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13th July 2023 are given below:

Product Name	Clopidogrel Bisulphate
existing capacity;	180 MTPA
existing capacity utilization;	180 MTPA
proposed capacity addition;	60 MTPA
period within which the proposed capacity is to be added;	stands completed on 24/03/2025
investment required;	Total Capex Rs 7.87 crore
mode of financing;	internal accruals
rationale.	To meet the increase in demand of Clopidogrel bisulphate in various market segments.

You are requested to please take the same on record.

Thanking you.

Yours faithfully,
for IOL Chemicals and Pharmaceuticals Limited

Abhay Raj Singh
Sr. Vice President & Company Secretary